Influenza Virus-Derived CD8 T Cell Epitopes: Implications for the Development of Universal Influenza Vaccines

Overview

Journal Immune Netw

Specialty Allergy & Immunology

Date 2024 Jul 8

PMID 38974213

Authors

Sang-Hyun Kim

Erica Espano

Bill Thaddeus Padasas

Ju-Ho Son

Jihee Oh

Richard J Webby

Young-Ran Lee

Chan-Su Park

Jeong-Ki Kim

Affiliations

Soon will be listed here.

Abstract

The influenza virus poses a global health burden. Currently, an annual vaccine is used to reduce influenza virus-associated morbidity and mortality. Most influenza vaccines have been developed to elicit neutralizing Abs against influenza virus. These Abs primarily target immunodominant epitopes derived from hemagglutinin (HA) or neuraminidase (NA) of the influenza virus incorporated in vaccines. However, HA and NA are highly variable proteins that are prone to antigenic changes, which can reduce vaccine efficacy. Therefore, it is essential to develop universal vaccines that target immunodominant epitopes derived from conserved regions of the influenza virus, enabling cross-protection among different virus variants. The internal proteins of the influenza virus serve as ideal targets for universal vaccines. These internal proteins are presented by MHC class I molecules on Ag-presenting cells, such as dendritic cells, and recognized by CD8 T cells, which elicit CD8 T cell responses, reducing the likelihood of disease and influenza viral spread by inducing virus-infected cell apoptosis. In this review, we highlight the importance of CD8 T cell-mediated immunity against influenza viruses and that of viral epitopes for developing CD8 T cell-based influenza vaccines.

References

Okoli G, Racovitan F, Abdulwahid T, Righolt C, Mahmud S . Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: A systematic review and meta-analysis of the evidence from test-negative design.... Vaccine. 2021; 39(8):1225-1240. DOI: 10.1016/j.vaccine.2021.01.032. View

Zhang H, Zheng H, Guo P, Hu L, Wang Z, Wang J . Broadly Protective CD8 T Cell Immunity to Highly Conserved Epitopes Elicited by Heat Shock Protein gp96-Adjuvanted Influenza Monovalent Split Vaccine. J Virol. 2021; 95(12). PMC: 8315956. DOI: 10.1128/JVI.00507-21. View

Sui Z, Chen Q, Fang F, Zheng M, Chen Z . Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine. 2010; 28(48):7690-8. DOI: 10.1016/j.vaccine.2010.09.019. View

Peteranderl C, Herold S, Schmoldt C . Human Influenza Virus Infections. Semin Respir Crit Care Med. 2016; 37(4):487-500. PMC: 7174870. DOI: 10.1055/s-0036-1584801. View

Wu T, Hu Y, Lee Y, Bouchard K, Benechet A, Khanna K . Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. J Leukoc Biol. 2013; 95(2):215-24. PMC: 3896663. DOI: 10.1189/jlb.0313180. View

Cullen J, McQuilten H, Quinn K, Olshansky M, Russ B, Morey A . CD4 T help promotes influenza virus-specific CD8 T cell memory by limiting metabolic dysfunction. Proc Natl Acad Sci U S A. 2019; 116(10):4481-4488. PMC: 6410826. DOI: 10.1073/pnas.1808849116. View

Hashimoto M, Kamphorst A, Im S, Kissick H, Pillai R, Ramalingam S . CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annu Rev Med. 2018; 69:301-318. DOI: 10.1146/annurev-med-012017-043208. View

Fuse S, Tsai C, Molloy M, Allie S, Zhang W, Yagita H . Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1. J Immunol. 2009; 182(7):4244-54. PMC: 2713929. DOI: 10.4049/jimmunol.0802041. View

Jazayeri S, Poh C . Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins. Vaccines (Basel). 2019; 7(4). PMC: 6963725. DOI: 10.3390/vaccines7040169. View

10.

Choi H, Lee H, Sohn H, Kim T . CD40 ligand stimulation affects the number and memory phenotypes of human peripheral CD8 T cells. BMC Immunol. 2023; 24(1):15. PMC: 10311846. DOI: 10.1186/s12865-023-00547-2. View

11.

Si Y, Wen Y, Kelly S, Chong A, Collier J . Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8 T cell responses. J Control Release. 2018; 282:120-130. PMC: 6309200. DOI: 10.1016/j.jconrel.2018.04.031. View

12.

Prigge A, Ma R, Coates B, Singer B, Ridge K . Age-Dependent Differences in T-Cell Responses to Influenza A Virus. Am J Respir Cell Mol Biol. 2020; 63(4):415-423. PMC: 7528914. DOI: 10.1165/rcmb.2020-0169TR. View

13.

Assarsson E, Bui H, Sidney J, Zhang Q, Glenn J, Oseroff C . Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol. 2008; 82(24):12241-51. PMC: 2593359. DOI: 10.1128/JVI.01563-08. View

14.

Restuccia A, Hudalla G . Tuning carbohydrate density enhances protein binding and inhibition by glycosylated β-sheet peptide nanofibers. Biomater Sci. 2018; 6(9):2327-2335. DOI: 10.1039/c8bm00533h. View

15.

Kervevan J, Chakrabarti L . Role of CD4+ T Cells in the Control of Viral Infections: Recent Advances and Open Questions. Int J Mol Sci. 2021; 22(2). PMC: 7825705. DOI: 10.3390/ijms22020523. View

16.

Jang Y, Seong B . The Quest for a Truly Universal Influenza Vaccine. Front Cell Infect Microbiol. 2019; 9:344. PMC: 6795694. DOI: 10.3389/fcimb.2019.00344. View

17.

Li J, Zhang Y, Zhang X, Liu L . Influenza and Universal Vaccine Research in China. Viruses. 2023; 15(1). PMC: 9861666. DOI: 10.3390/v15010116. View

18.

Comber L, O Murchu E, Jordan K, Hawkshaw S, Marshall L, ONeill M . Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. Rev Med Virol. 2022; 33(3):e2330. DOI: 10.1002/rmv.2330. View

19.

Hensen L, Illing P, Clemens E, Nguyen T, Koutsakos M, van de Sandt C . CD8 T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph. Nat Commun. 2021; 12(1):2931. PMC: 8132304. DOI: 10.1038/s41467-021-23212-x. View

20.

Singh-Jasuja H, Toes R, Spee P, Munz C, Hilf N, Schoenberger S . Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med. 2000; 191(11):1965-74. PMC: 2213530. DOI: 10.1084/jem.191.11.1965. View